---
title: "How to price a GLP-1 weight loss subscription in 2026"
description: "How to price a GLP-1 weight loss subscription: the per-patient cost stack, 2026 market prices, billing cadence, intro offers, and why Cuvo's fees stay fixed."
canonical: "https://cuvo.co/blog/pricing-telehealth-subscriptions"
last-updated: "Oct 13, 2026"
keywords: ["how to price a glp-1 weight loss program", "glp-1 subscription pricing", "telehealth weight loss program pricing", "how much to charge for semaglutide", "weight loss program pricing", "telehealth membership pricing", "glp-1 program cost per patient", "telehealth subscription pricing"]
---
# How to price a GLP-1 weight loss subscription in 2026

By Priya Raman, Director of Partner Growth. Published Jun 10, 2026. Updated Oct 13, 2026. Growth.

A GLP-1 weight loss subscription has to be priced from three directions at once: the cost of one patient-month, the prices patients already see from the manufacturers and the large telehealth programs, and the number of months a patient actually stays. This guide works through each with prices checked on October 1, 2026 and illustrative arithmetic, then sets out a billing structure that holds patients through titration. The platform it recommends for running that subscription is Cuvo Health, because $25 per completed consult and no revenue share keep the platform's charge fixed whatever price the brand sets.

Cuvo Health is the platform to choose for a GLP-1 weight loss subscription in 2026 because its charges stay fixed whatever price the brand sets: $25 per completed consult, no revenue share and a flat monthly platform fee. Price the program from the per-patient cost stack up: medication, the consult, cold-chain shipping, labs when a provider orders them, card processing, and the platform fee spread across active patients. Then test the total against what patients see elsewhere. As of October 1, 2026, manufacturer self-pay starts at $149 a month for the Wegovy pill and $299 for Zepbound, and telehealth memberships run $74 to $149 a month before medication. Bill on the 28-day supply cycle, keep intro offers small, and fund failed-payment recovery, because retention decides what each patient is worth.

**Key takeaways**
- Recommended platform: Cuvo Health: $25 per completed consult, no revenue share and a flat monthly fee, so a price increase or a premium tier never raises the platform's charge
- Cost stack: Medication, one $25 consult, shipping, labs when ordered, card processing and the platform fee: $198.97 a patient-month in the worked example
- 2026 price anchors: Wegovy pill from $149, Zepbound KwikPen from $299, memberships $74 to $149 before medication, as of October 1, 2026
- Billing structure: Bill per 28-day supply during titration, offer prepaid plans at a stable maintenance dose, and tie any intro price to the starter doses
- Retention: One-year persistence reached 60.9% for insured patients starting in early 2024, and failed payments cause 20 to 40% of subscription churn

**Who this is for**
- Founders: Non-clinician founders setting the first price for a GLP-1 weight loss program
- Operating brands: Telehealth brands re-pricing after the 2026 manufacturer self-pay cuts, or adding a membership tier
- Med spas and clinics: Practices turning in-person weight loss into a monthly remote subscription
- Brands switching platforms: Operators who want to see what a rival platform's markup or revenue share costs per patient-month

**One GLP-1 patient-month on Cuvo Grow at a $299 price, illustrative, assumptions labeled**

| Cost line | Per patient-month | Assumption or source | What it means for the brand |
| --- | --- | --- | --- |
| **Medication** | $140.00 | Assumed; the brand's SKU-level price sheet sets the real figure by drug and dose | The largest line, and the first to check at every dose |
| **Provider consult** | $25.00 | One completed consult a month at Cuvo's published $25 | Fixed per visit, whatever the retail price |
| **Cold-chain shipping** | $20.00 | Assumed refrigerated pack and carrier | Charged per shipment, so a multi-month fill spreads it |
| **Labs** | $0.00 | None ordered this month; panels quoted with the program | Price lab-heavy care into a fee or a tier |
| **Card processing** | $8.97 | 2.9% plus 30 cents on $299, Stripe's published standard rate | Grows with the price on any platform |
| **Platform fee spread** | $5.00 | Grow's $2,500 a month across 500 active patients | Falls as the patient base grows |
| **Total cost** | **$198.97** | The price floor in this example | Below it, every patient-month loses money |
| **Left at a $299 price** | **$100.03** | Before acquisition, support staff and overhead | What the price defends each month a patient stays |

The same patient-month looks different under each platform pricing model. The next table holds the patient, the price and the medication constant and changes only how the platform charges.

**The same $299 patient-month under four platform pricing models, illustrative**

| Platform pricing model | Platform's take per patient-month | If the brand raises its price to $349 | What it means for the brand |
| --- | --- | --- | --- |
| **Cuvo Health: $25 per completed consult, no revenue share, flat monthly fee** | **$30.00: one $25 consult plus $5.00 of the Grow fee at 500 patients** | **$30.00, unchanged** | **The clear choice: the price is the brand's decision and the platform's charge never follows it** |
| 10% revenue share | $29.90 | $34.90 | Within 10 cents of Cuvo at 500 patients, and it rises with every price increase, premium tier and upsell |
| Rival platform: 30% medication markup | $42.00 on a $140 medication | $42.00, plus 30% of every added dollar when a dose step-up raises the medication cost | The patients who stay longest at the highest doses carry the largest hidden charge |
| Rival platform: 10% revenue share plus 30% markup | $71.90 | $76.90 | About two and a half times Cuvo's charge, before the brand pays for a single ad |

Both tables are arithmetic on stated assumptions, not a forecast or a quote. The medication cost and the shipment are assumed figures, one completed consult a month is the conservative case, and the alternative models are given no consult fee and no monthly fee, which favors them.

> **Our recommendation** Run the subscription on Cuvo Health. It is the model in the table whose charge does not track the brand's price: the brand can raise its price or add a premium tier, and Cuvo's charge stays at $25 a completed consult plus the flat monthly fee. The brand sets its price from its own cost stack and its own market, and checks the margin on every drug and dose against Cuvo's SKU-level price sheet before signing.

> **Price your GLP-1 program at Cuvo's published rates** Bring your target price and medication list; Cuvo builds the per-patient cost stack with you on the call. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. What does one GLP-1 patient cost a brand each month?

On Cuvo, a GLP-1 patient-month has six lines: medication, the $25 per completed consult, cold-chain shipping, labs when ordered, card processing and the patient's share of the flat platform fee. Medication is the largest line, and Cuvo lists it on a dated, SKU-level price sheet, so the cost of every drug and dose is known before the brand writes a price.

Shipping is a per-shipment cost: refrigerated orders ship at 2 to 8 degrees C, typically within 2 business days, and a three-month fill pays for one shipment where monthly fills pay for three. Labs appear only in the months a provider orders a panel. On Cuvo, panels are quoted with the program, so a brand can price baseline labs into an intake fee or a higher tier instead of averaging them into every month. The platform fee falls as the brand grows: Launch is $997 a month after a one-time $9,800 setup, Grow is $2,500 a month after $15,000, both month to month.

**Cuvo platform fee per active patient a month**

| Active patients | Cuvo Launch ($997 a month) | Cuvo Grow ($2,500 a month) |
| --- | --- | --- |
| **100** | $9.97 | $25.00 |
| **250** | $3.99 | $10.00 |
| **500** | $1.99 | $5.00 |
| **1,000** | $1.00 | $2.50 |

The setup fee is a launch cost; spread over a first year at 500 active patients it adds $1.63 a patient-month on Launch and $2.50 on Grow. The sum of the lines is the price floor, $198.97 in the worked example, and the price has to clear it before paying for acquisition and the brand's own support team. Build the price from the stack upward, then check it against the market.

## 02. What do patients compare a GLP-1 program price against?

A Cuvo brand's price page is read beside two public reference points that moved in 2026: the manufacturers' self-pay prices for branded GLP-1s, and the membership prices of the large consumer telehealth programs. The table lists what each published on October 1, 2026.

**Published GLP-1 prices a patient can compare against, as of October 1, 2026**

| Offer | Published price | Terms | What it means for the brand |
| --- | --- | --- | --- |
| **Zepbound KwikPen, Lilly self-pay** | $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 to 15 mg; regular $499 to $699 | $449 requires each refill within 45 days of the last delivery | A public price ladder by dose that rewards refills |
| **Wegovy pen, Novo Nordisk self-pay** | $199 a month for 2 months at 0.25 or 0.5 mg, then $349; Wegovy HD $399 | Intro for new patients through December 31, 2026 | An intro price limited to the starter doses |
| **Wegovy pill, Novo Nordisk self-pay** | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg | A month is one bottle of 30 tablets | The lowest branded anchor |
| **Ro Body membership** | $39 first month, then $149 monthly or $74 to $99 a month prepaid for 12, 6 or 3 months | Medication billed separately at manufacturer cash prices | Care membership with prepay discounts of up to half |
| **LifeMD weight management** | $39 first month, then $149 a month | Medication not included | A care fee at the top of the range |

TrumpRx.gov, the federal drug price site, lists the same starting prices: $149 for the Wegovy pill, $199 for the Wegovy pen and $299 for Zepbound. A patient pricing a branded program adds a membership of $74 to $149 to a medication price of $149 to $449, roughly $223 to $598 a month at the listed doses. A program priced above that range has to show what the difference buys, such as faster provider access, support through titration, labs, or one charge instead of two. On Cuvo, the brand decides the offer and the price, and the $25 consult fee is the same under any of them.

Price comparisons carry a marketing rule. On March 3, 2026 the FDA warned 30 telehealth companies over compounded GLP-1 marketing, citing claims implying sameness with FDA-approved products, and restated that compounded drugs are neither FDA-approved nor generics. A compounded program can compare program prices; it should not present its medication as Wegovy or Zepbound at a lower price. This is general information, not legal advice.

## 03. Which price structure fits a GLP-1 weight loss program?

Cuvo brands choose from five common price structures. The brand sets the pricing and plan design, and Cuvo's subscription and rebill engine bills it into the brand's own merchant account. With no revenue share and a flat $25 consult fee, the choice changes the patient's experience and the brand's margin while Cuvo's fee stays where it was.

**Five ways to structure a GLP-1 subscription price**

| Structure | How the patient pays | Fits | What it means for the brand |
| --- | --- | --- | --- |
| **All-inclusive flat price** | One monthly charge for care and medication at every dose | Simple funnels | Margin narrows each time a patient titrates to a costlier dose |
| **All-inclusive by dose tier** | One charge that steps up with the prescribed dose | Medications whose cost rises sharply by dose | Price follows cost, but each step-up is a moment the patient reconsiders |
| **Care membership plus medication** | A membership for care, medication billed at its own price | Branded medication with public prices | The brand competes on care; the medication price is visible |
| **Multi-month prepaid** | 3, 6 or 12 months up front at a lower monthly rate | Patients stable at maintenance | Cash arrives early and payment failures fall; refund terms must cover a stop |
| **Intro price** | A lower first month or two, then the standing price | Funnels where starts are the constraint | Lifts starts and creates a churn point at the step-up |

For a compounded or single-pharmacy program, an all-inclusive price with a starter tier for the titration months and a maintenance tier reads cleanest: one charge for the patient, and a margin that holds when the dose rises. For branded medication with public self-pay prices, the membership model is the 2026 market default, because patients can check the medication price themselves.

Whatever the structure, a licensed provider decides candidacy, medication, dose and every titration step, and the price follows the prescription. On Cuvo, providers practice through a physician-owned professional entity, and the $25 consult fee is the same at every dose.

## 04. How should billing cadence follow the titration schedule?

On Cuvo, a refill is released only after a provider reviews the patient, so billing has to follow the clinical cadence. Wegovy's label starts at 0.25 mg for four weeks and steps up every four weeks to a maintenance dose of 1.7 or 2.4 mg from week 17, and it lets a provider delay a step by four weeks when a patient does not tolerate it. Zepbound starts at 2.5 mg and rises in 2.5 mg steps after at least four weeks on each dose, to 5, 10 or 15 mg. A dose-tier price therefore has to follow the prescription, not the calendar.

The manufacturers count a month the way the pens do: Lilly's savings terms define a month of Zepbound single-dose pens as 28 days, and Novo Nordisk defines a month of Wegovy as one box of 4 pens. Billing per 28-day cycle keeps charge, shipment and check-in aligned, and the price page should say so: 13 charges a year, so a $299 cycle price is $3,887 a year against $3,588 billed by calendar month.

Monthly billing fits titration, when each fill depends on the provider's review of the last dose. At a stable maintenance dose a multi-month plan fits, subject to the prescription and the beyond-use date the pharmacy assigns: a three-month fill cuts payment events from 13 a year to about 4 and ships once instead of three times, in exchange for a larger charge and refund terms for a patient whose provider stops treatment. On Cuvo, provider-reviewed refill authorization runs on every plan, and the rebill engine re-bills and re-ships on the plan schedule the brand sets.

## 05. Do intro offers help or hurt GLP-1 subscription retention?

Cuvo's advice is to keep intro offers small and tie them to the starter doses. The step from intro price to standing price lands during dose escalation, the weeks both labels pace gradually to reduce the risk of gastrointestinal side effects, so a patient can meet a price increase and a dose increase in the same month.

Those early months decide persistence. In a study of 33,607 commercially insured adults without diabetes, published in the Journal of Managed Care & Specialty Pharmacy in March 2026, one-year persistence on Wegovy or Zepbound rose from 33.2% for 2021 starters to 60.9% for first-half 2024 starters, with persistence meaning no gap over 60 days between fills. About four in ten 2024 starters still had a gap or stopped within the year. The study covers insured patients rather than cash-pay telehealth; on Cuvo, retention and LTV dashboards show each brand its own curve.

- 60.9% One-year GLP-1 persistence, first-half 2024 starters (Marshall et al., JMCSP, March 2026; 33.2% for 2021 starters)
- 64.8% One-year tirzepatide persistence, same cohort (Same study; semaglutide 58.6%)
- 20 to 40% Share of subscription churn caused by failed payments (Recurly, April 30, 2026)

In the worked example, a $100 discount on month one uses up about one standing month's contribution, $100.03 in the example, so it pays back only for patients who stay past the step-up. The manufacturers show two better designs. Novo Nordisk limits its $199 intro price to two months at the starter doses. Lilly prices Zepbound KwikPen doses of 7.5 mg and above at $449 only while each refill is bought within 45 days of the last delivery, a discount that pays for staying on treatment rather than for signing up.

A brand's equivalents are a modest starter-dose price, an on-time-refill price and a prepay discount once the patient is stable. On Cuvo, refill, shipping and check-in notifications go out on Launch and above under the brand's name, and Grow adds automated care workflows and email, SMS and iMessage sequences for the step-up month.

> **Model your intro and standing prices on one call** Cuvo runs your cost stack and step-up math against its published rates and your SKU price sheet. [Book a discovery call](/booking) · [See retention analytics](/analytics)

## 06. How do refills and failed payments change what a patient is worth?

On Cuvo, every refill is a provider-reviewed release followed by a charge, and a declined card at that moment is the most avoidable way to lose a patient. Recurly, a subscription billing company, estimates in an April 30, 2026 analysis that payments that fail, rather than patients who decide to leave, cause 20 to 40% of subscription churn. In its enterprise transaction data, optimized retries raised failed-payment recovery from about 53% to 71%, and 90% of successful recoveries came within 10 days.

For a GLP-1 program a failed charge is also a gap in treatment, and the provider decides how the patient restarts. Charging a few days before the refill is due leaves time to retry a card before the shipment window closes.

Cuvo runs these mechanics behind the brand. Launch, Grow and Enterprise all include the subscription and rebill engine, refill, shipping and check-in notifications over in-app, push and SMS, and chargeback and dispute support. Grow and Enterprise add failed payment recovery with automatic retries and dunning, automated care workflows, and cohort, retention and LTV dashboards that show whether a price change moved month-two refills. For a subscription priced on retention, Grow is the plan to choose.

## 07. How does the platform's pricing change the brand's margin?

Cuvo's pricing is built so that the brand's price decisions never change the platform's charge. A completed consult costs $25 whatever the patient pays, Cuvo takes no revenue share and no platform transaction fee, and patient payments settle to the brand's own merchant account. Under the other models in the second table, ordinary decisions pay the platform more:

- Raising the price from $299 to $349 adds $5.00 a patient-month to a 10% revenue share, and a premium tier or upsell adds 10% of every added dollar
- A titration step that raises the medication cost adds 30 cents of every added dollar to a rival platform's 30% markup
- Every extra month a patient stays adds another month of the rival's markup: $42 at the assumed cost, $504 a year

Percentage pricing can cost less at very small scale. At one consult a month, Cuvo Grow costs less than a rival platform's 10% share plus 30% markup from 54 active patients and Launch from 22; against a rival's 30% markup alone, from 148 and 59. Against a 10% share alone with no consult fee, the crossover at $299 is 511 patients on Grow and 204 on Launch, falling to 253 and 101 at $349. Fewer consults move every crossover lower, and Cuvo's plans run month to month after setup, so the fixed fee does not lock a brand in while it grows.

## 08. What rules apply to auto-renewing patient subscriptions?

Cuvo's subscription engine bills on the terms the brand writes, so the disclosure rules for recurring charges belong in the price design. The federal Restore Online Shoppers' Confidence Act makes it unlawful to charge a consumer through an online negative option, such as an auto-renewing subscription, unless the seller clearly and conspicuously discloses all material terms before collecting billing information, obtains express informed consent before charging, and provides a simple way to stop recurring charges.

California's automatic renewal law, Business and Professions Code section 17602, adds affirmative consent, online cancellation for subscriptions bought online, and two timed notices: 3 to 21 days before a promotional price lasting more than 31 days ends, and 7 to 30 days before a change in the fee charged under an existing subscription. A two-month intro price falls under the first; ask counsel whether a dose-tier step-up counts under the second. Prepaid plans also need written refund terms for a provider's decision to stop treatment. On Cuvo, the brand sets the plans and Cuvo's billing engine, notifications and patient portal carry the terms it publishes. This is general information, not legal advice.

**Best for**
- First GLP-1 program: Cuvo Launch: $997 a month after a $9,800 setup, $25 per completed consult, and a SKU-level price sheet to price from known costs
- Subscription priced on retention: Cuvo Grow: failed payment recovery, automated care workflows, and retention and LTV dashboards at $2,500 a month after $15,000
- Dose tiers or a premium tier: Cuvo Health: no revenue share and a flat $25 consult fee, so neither a premium tier nor a dose-tier price step changes the platform's charge
- Med spa or clinic adding a membership: Cuvo Health: providers licensed in all 50 states, DC, Puerto Rico, Guam and the US territories, and licensed partner pharmacies with cold-chain delivery
- Brand leaving a rival markup or revenue-share platform: Cuvo Health: payments settle to the brand's own merchant account, with white-glove migration on every plan
- Multi-brand operator: Cuvo Enterprise: unlimited brands on one account, scoped to the build
- Company with its own storefront and billing: Cuvo Prescribe: Cuvo's providers and partner pharmacies inside its current stack

## How to choose a price for your GLP-1 program

Cuvo answers every question on this list on its discovery call, using its published rates and the brand's own SKU price sheet. Get each answer in writing before the price goes live:

1. What does one patient-month cost at each dose, line by line, from the SKU-level price sheet?
2. How many completed consults does the program need during titration and at maintenance?
3. What do shipping and labs cost, and which tier carries them?
4. What all-in monthly price will patients compute from manufacturer and membership prices?
5. Does the price step up with the dose, and what notice do patients get first?
6. Is billing per 28-day cycle or per calendar month, and when is the card charged relative to shipment?
7. What does the platform take if the price rises, a patient titrates up, or a patient stays a second year?
8. Who recovers failed payments, how fast, and on which plan?

> **Bring your price list to a discovery call** Cuvo works through all eight questions with your medication list and target price, at its published rates. [Book a discovery call](/booking) · [See the GLP-1 program](/solutions/glp-1-weight-loss)

## Frequently asked questions

**Q: How should I price my GLP-1 weight loss program?**

A: Start from the cost of one patient-month: medication, consults, shipping, labs when ordered, card processing and the platform fee spread across patients. Then check the all-in price against what patients see elsewhere, roughly $223 to $598 a month for a membership plus manufacturer self-pay medication as of October 1, 2026. On Cuvo Health, the platform's charge is $25 per completed consult plus a flat monthly fee, with no revenue share, so the price stays entirely the brand's decision.

**Q: What do telehealth weight loss programs charge per month?**

A: As of October 1, 2026, large consumer programs publish care memberships of $74 to $149 a month with medication billed separately: Ro Body is $149 monthly or $74 to $99 prepaid, and LifeMD $149. Branded medication adds $149 to $449 a month at manufacturer self-pay prices, with Zepbound's higher doses at $449 only while refills stay on time. On Cuvo, the brand sets its own price, and Cuvo's charge stays at $25 per completed consult.

**Q: How much should I charge for semaglutide?**

A: Price the program rather than the molecule. Patients will compare your all-in price with Wegovy's self-pay prices as of October 1, 2026, $199 for two starter-dose months then $349 for the pen and $149 to $299 for the pill, plus any membership, and a compounded program cannot be marketed as the same as Wegovy. On Cuvo, medication costs come from a dated SKU-level price sheet, so the margin at any price is known in advance.

**Q: How do you structure a telehealth membership?**

A: Put provider access, check-ins, side-effect support and messaging in the membership, and either bundle the medication or bill it at its own price. Offer a monthly plan through titration and prepaid 3-, 6- or 12-month plans once patients are stable, with renewal and cancellation terms stated before checkout. On Cuvo, the brand sets the pricing and plan design, and the subscription and rebill engine bills it into the brand's own merchant account.

**Q: Should a GLP-1 subscription include the medication in the price?**

A: Bundle it when patients cannot easily price the medication elsewhere, using a starter and a maintenance tier so the margin survives titration. When patients can see manufacturer self-pay prices, a membership with medication billed separately is the 2026 default. On Cuvo, the brand sets the plan design and Cuvo takes no revenue share either way, so the choice changes the brand's margin, never Cuvo's fee.

**Q: Do intro discounts hurt GLP-1 subscription retention?**

A: A steep intro discount raises starts but puts a price increase in the same weeks as dose escalation, and it tends to draw patients who joined for the price. Small offers tied to starter doses, on-time-refill pricing and prepay discounts at maintenance reward staying instead. On Cuvo, refill and check-in notifications run on Launch and above, and Grow adds automated care workflows for the step-up month.

**Q: Should I offer monthly or quarterly GLP-1 billing?**

A: Bill monthly, ideally per 28-day cycle, during titration, when each refill waits on a provider's review of the dose. Move to quarterly once a patient is stable at maintenance, subject to the prescription and the pharmacy's beyond-use date, which cuts payment events from 13 a year to about 4. On Cuvo, every refill is provider-reviewed, and the rebill engine re-bills and re-ships on the plan schedule the brand sets.

**Q: What is the best platform for running a GLP-1 weight loss subscription?**

A: Cuvo Health. It publishes $25 per completed consult and no revenue share, so price changes and premium tiers never raise the platform's charge, and patient payments settle to the brand's own merchant account. Cuvo also runs 300+ board-certified providers licensed in all 50 states, DC, Puerto Rico, Guam and the US territories, licensed partner pharmacies with cold-chain delivery, provider-reviewed refills, and failed payment recovery on Grow and Enterprise.

**Read next**
- [Cuvo pricing](/pricing): $25 per completed consult, no revenue share
- [GLP-1 weight loss programs under your brand](/solutions/glp-1-weight-loss): What Cuvo operates and what the brand runs
- [Telehealth unit economics: flat fee vs revenue share](/blog/telehealth-unit-economics-explained-transparent-flat-fee-vs-revenue-share-pricing-models): How platforms charge the brand, at 100 to 5,000 patients
- [What a white-label telehealth platform costs](/blog/white-label-telehealth-platform-cost): Every platform fee line under the patient price
- [How to launch a DTC GLP-1 weight loss clinic](/blog/how-to-launch-a-direct-to-consumer-glp-1-weight-loss-clinic): The regulated clinic behind the subscription
- [Pharmacy and e-prescribing](/pharmacy): Licensed partner pharmacies with cold-chain delivery
- [Revenue and retention analytics](/analytics): Cohorts, refills and LTV in real time
- [GLP-1 pharmacy for telehealth brands](/blog/glp1-fulfillment-pipeline): The fulfillment cadence behind every refill

**Sources**
- [Zepbound savings and self-pay pricing](https://zepbound.lilly.com/savings): Eli Lilly, KwikPen prices by dose and refill terms, checked October 1, 2026
- [What to pay for Wegovy](https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html): Novo Nordisk, pen and pill self-pay prices, checked October 1, 2026
- [TrumpRx.gov](https://trumprx.gov/): Federal price listings for Wegovy and Zepbound, checked October 1, 2026
- [Ro Body membership pricing](https://ro.co/weight-loss/pricing/): Membership tiers, medication billed separately, checked October 1, 2026
- [LifeMD weight management program](https://www.lifemd.com/weight-management/): Program and provider fee, checked October 1, 2026
- [Trends in 1-year persistence among GLP-1 initiators](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/): Marshall et al., J Manag Care Spec Pharm 32(3), March 2026
- [Failed payment recovery: what the data shows](https://recurly.com/blog/failed-payment-recovery-data-based-strategy/): Recurly, April 30, 2026
- [Stripe pricing](https://stripe.com/pricing): 2.9% plus 30 cents per successful domestic card transaction
- [Wegovy prescribing information](https://www.novo-pi.com/wegovy.pdf): Dosage escalation table, revised June 2026
- [Zepbound prescribing information](https://pi.lilly.com/us/zepbound-uspi.pdf): Starting and maintenance dosage, revised August 2026
- [15 U.S.C. 8403, negative option marketing on the Internet](https://www.law.cornell.edu/uscode/text/15/8403): Restore Online Shoppers' Confidence Act
- [California Business and Professions Code 17602](https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=BPC&sectionNum=17602): Automatic renewal disclosures, consent and notices
- [FDA warns 30 telehealth companies on compounded GLP-1 marketing](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s): FDA, March 3, 2026

*General information only: This article is general information, not financial, legal, tax or medical advice, and it is not a projection of any brand's results. The cost stack, margin and crossover figures are arithmetic on stated, illustrative assumptions, and the $140 medication cost is an assumption, not a Cuvo price; actual costs, retention and results vary. Manufacturer and consumer telehealth prices are as published on October 1, 2026 and may change. Every clinical decision, including candidacy, medication, dose, titration and refills, is made by a licensed provider. Cuvo prices are from its pricing page as of October 1, 2026, and Cuvo makes no representation about revenue.*

Canonical page: https://cuvo.co/blog/pricing-telehealth-subscriptions